Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7723121 | 0.84 | CALM1 (0.58) | CALM1LOXL2BCL2BCL2L1LTA4H | |
| SCHEMBL14941759 | 0.72 | CALM1 (0.55) | CALM1LOXL2TDP1BCL2BCL2L1 | |
| SCHEMBL6249409 | 0.71 | CALM1 (0.42) | CALM1TDP1BCL2BCL2L1LTA4H | |
| SCHEMBL2997577 | 0.69 | CALM1 (0.41) | CALM1TDP1BCL2BCL2L1TSHR | |
| SCHEMBL6483541 | 0.67 | TSHR (0.42) | LOXL2TDP1TSHRALDH1A1NPC1 | |
| SCHEMBL5698082 | 0.67 | CALM1 (0.42) | CALM1TDP1BCL2BCL2L1TSHR | |
| Diphenylmethane SCHEMBL3792579 | 0.66 | CALM1 (1.00) | CALM1LOXL2BCL2BCL2L1LTA4H | |
| Diphenylmethane SCHEMBL4361124 | 0.66 | CALM1 (1.00) | CALM1LOXL2BCL2BCL2L1LTA4H | |
| Diphenylmethane SCHEMBL14763944 | 0.66 | CALM1 (1.00) | CALM1LOXL2BCL2BCL2L1LTA4H | |
| Diphenylmethane SCHEMBL1303 | 0.66 | CALM1 (1.00) | CALM1LOXL2BCL2BCL2L1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023036995-A1 | ALKYNYLCARBINOLS WITH HIGH CYTOTOXICITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-03-16 | — | — | WO | claimed |
| EP-3010906-B1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS | AB SCIENCE (FR) | 2019-06-12 | — | — | EP | claimed |
| EP-1737815-B1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON INC (US) | 2016-12-21 | — | — | EP | claimed |
| US-9102601-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | claimed |
| US-20150141378-A1 | NITROXYL PROGENITOR COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | claimed |
| US-20150080386-A1 | Compounds For The Treatment Of Proliferative Disorders | SYNTA PHARMACEUTICALS CORP (US) | 2015-03-19 | — | — | US | claimed |
| US-8785451-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-22 | — | — | US | claimed |
| US-8648071-B2 | Hydrazonamide compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-11 | — | — | US | claimed |
| US-20130210821-A1 | Methods for Treating Obesity | ZAFGEN, INC. | 2013-08-15 | — | — | US | claimed |
| US-8450500-B2 | Pyrrole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-28 | — | — | US | claimed |
| US-20050004111-A1 | Degenerative joints disease; osteoarthritis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-06 | — | — | US | claimed |
| US-20040214857-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-10-28 | — | — | US | claimed |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | US | claimed |
| WO-2004060883-A1 | PYRIMIDINE-4,6-DICARBOXYLIC ACID DIAMIDES FOR USE AS SELECTIVE MMP 13 INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-22 | — | — | WO | claimed |
| WO-2004041788-A1 | NOVEL PYRIMIDINE-4,6-DICARBOXAMIDES FOR THE SELECTIVE INHIBITION OF COLLAGENASES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-21 | — | — | WO | claimed |
| US-20040067980-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-08 | — | — | US | claimed |
| US-6706715-B2 | REVERSIBLE INHIBITORS OF THE BLOOD CLOTTING ENZYME FACTOR VIIA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-03-16 | — | — | US | claimed |
| WO-2003104221-A1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-18 | — | — | WO | claimed |
| EP-1369420-A1 | Inhibitors of the GPib - vWF interaction | Aventis Pharma Deutschland GmbH (DE) | 2003-12-10 | — | — | EP | claimed |
| US-20030176439-A1 | Urea derivatives with antiproteolytic activity | AVENTIS PHARMA DUTSCHLAND GMBH | 2003-09-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | MMP13, DPYD, MMP1 | CALM1 2373/4885LOXL2 2160/4885TDP1 86/4885 |
| US-20150080386-A1 | Compounds For The Treatment Of Proliferative Disorders | HSP90AB1, HSPE1, HSPB1 | CALM1 1108/4885LOXL2 3327/4885TDP1 993/4885 |
| US-20130210821-A1 | Methods for Treating Obesity | LIPC, PNLIP, FABP4 | CALM1 2362/4885LOXL2 1131/4885TDP1 3606/4885 |
| US-20050004111-A1 | Degenerative joints disease; osteoarthritis | MMP13, ADAMTS13, DPYD | CALM1 3632/4885LOXL2 1605/4885TDP1 174/4885 |
| US-20150141378-A1 | NITROXYL PROGENITOR COMPOUNDS AND METHODS OF USE | HMOX2, NNMT, HMOX1 | CALM1 2496/4885LOXL2 38/4885TDP1 897/4885 |
| US-20040067980-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | F13B, F11, F12 | CALM1 4043/4885LOXL2 2856/4885TDP1 3209/4885 |
| US-20030176439-A1 | Urea derivatives with antiproteolytic activity | F7, F11, F12 | CALM1 4479/4885LOXL2 1328/4885TDP1 535/4885 |
| US-20040214857-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDK4, CDS2, DDB1 | CALM1 777/4885LOXL2 4541/4885TDP1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.